undamentalytics Newsletter
Sign in

Cellyan Biotechnology Co., Ltd balance sheet

At the end of fiscal 2026, Cellyan Biotechnology Co., Ltd had total assets of $12.8m, total liabilities of $3.3m and shareholders' equity of $9.6m. It held $221,841 in cash against $877,904 of debt: net debt of $656,063.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Mar 20232024Mar 20242025Mar 20252026Mar 2026
Cash and equivalents—110
Receivables—45—
Inventory—110
Total current assets—8912
Total assets—9913
Total current liabilities—333
Short-term debt—001
Long-term debt—12—
Total debt—121
Total liabilities—443
Shareholders' equity14510
Net debt (negative = net cash)—111

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: COSM vs HKPDHKPD vs YIHKPD vs HSIC

More: Health Care Distributors stocks compared, Health Care sector, rankings of US companies

Figures from Cellyan Biotechnology Co., Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cellyan Biotechnology Co., Ltd.